Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the leaders from the rest.
UroGen Pharma has invested in IntraGel Therapeutics and secured an exclusive option to license Tumocure, and Lupin's ...
FDA approval in adult FOP targets disease-driving Activin A biology, addressing progressive heterotopic ossification that ...
In pharma's AI transformation, the technology was never the hard part — fixing the operating model that has to act on what AI ...
Pharmaceutical reshoring is constrained by supplier qualification, process validation, FDA compliance readiness, workforce ...
A partnership roundup covers deals from IntraGel Therapeutics/UroGen Pharma and Lupin/Tenpoint Therapeutics, FDA approves ...
Heidi Overton, a UNM-trained physician with Johns Hopkins general surgery training, was selected for FDA commissioner after ...
How drug pricing, tariffs, and manufacturing decisions are becoming connected. For years, pharmaceutical companies could ...
Spherix's VP of market access discusses how the IRA's maximum fair price is reshaping payer strategy, formulary design, and patient out-of-pocket costs far beyond negotiated drugs.
Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...
Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the ...
President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results